Vizex Investments Ltd
financial consultations

Last news

Transenterix announces 1st US sale

Nov 13, 2017 14
November 13th. Transenterix Inc…

We no longer recommend Array Biopharma Inc

Nov 11, 2017 10
November 11th 2017. We are withdrawing…

Short term investment recommendation -- Baxter International Inc

April 29th 2017 Baxter International Inc (NYSE.BAX)  through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision

 

On May 1st - the day we published the recommendation - the stock could be bought at 55.43$ per share.

On May 5th - the stock could be sold at 56$ per share

Investors profit 1% 

The recommendation is no longer valid. 

Вайзекс Инвестментс ООД © 2015 | Всички права запазени